Editas Medicine (EDIT) Announces 3.5M Share Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/26/2026
- Wall St futures subdued as Nvidia results, inflation take center stage
- Oil settles down more than 3%; investors shrug off US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Boston Scientific discloses cybersecurity incident causing global disruption
- Wall Street ends higher as tech rebounds before Nvidia results
- Six Flags to move headquarters from Charlotte to Arlington, Texas
- Intuit (INTU) Tops Q4 EPS; Offers FY27 Guidance
- Oppenheimer Upgrades Capricor Therapeutics (CAPR) to Outperform 'on Approval Optimism'
Editas Medicine Announces Offering of Common Stock
January 19, 2021 4:01 PM ESTCAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading gene editing company, today announced that it intends to offer and sell 3,500,000 shares of its common stock in an underwritten public offering. Editas Medicine intends to grant the underwriters a 30-day option to purchase up to an additional 525,000 shares of its common stock. All of the shares in the offering are to be sold by Editas Medicine.
J.P. Morgan and Morgan Stanley are acting as joint book-running managers for the offering. Cowen and Credit... More
